Caesars Entertainment misses Q2 earnings expectations, shares edge lower
BURLINGTON, N.C.—LabCorp Holdings Inc. (NYSE:LH), a prominent player in the Healthcare Providers & Services industry with a market capitalization of $19.3 billion, saw Executive Vice President, President of Diagnostics, and Chief Operating Officer Mark S. Schroeder sell 2,635 shares of the company’s common stock on March 28, 2025. The shares were sold at an average price of $231.67, totaling approximately $610,450. This transaction was conducted under a pre-arranged trading plan in accordance with Rule 10b5-1.
A day prior, on March 27, Schroeder acquired 4,840 shares at no cost, as part of a performance award granted in February 2022. Additionally, he disposed of 2,205 shares on the same day to cover tax obligations, with these shares valued at $231.67 each, amounting to $510,832. According to InvestingPro data, LabCorp maintains a strong financial health score of 2.78 (GOOD), with management actively pursuing share buybacks.
Following these transactions, Schroeder’s direct ownership stands at 4,960 shares. For detailed insights into LabCorp’s valuation metrics and 7 additional exclusive ProTips, visit InvestingPro.
In other recent news, Laboratory Corporation of America (LabCorp) has announced an agreement to acquire select assets from BioReference Health for up to $225 million. This acquisition, expected to close in the second half of 2025, includes oncology-focused laboratory testing businesses and is anticipated to contribute immediately to LabCorp’s earnings. The assets currently generate approximately $85 million to $100 million in annual revenue, aligning with LabCorp’s strategy to enhance its presence in oncology testing. Truist Securities has maintained a Buy rating for LabCorp, with a price target of $285, citing the strategic fit and financial benefits of the acquisition. Citi analysts have also upgraded LabCorp’s stock from Neutral to Buy, raising the price target to $300, reflecting optimism about the company’s market position and financial performance. Additionally, LabCorp has launched the Labcorp Plasma CompleteTM, a liquid biopsy test for advanced cancer care, which offers comprehensive genomic profiling to support personalized treatment plans. This new test has been validated for clinical accuracy and reliability, further enhancing LabCorp’s oncology portfolio. These recent developments underscore LabCorp’s ongoing strategic efforts to expand its diagnostic capabilities and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.